
AN EXTENSIVE PRODUCT PIPELINE
Applications Filed and Approved by the USDA
In 2019, the FDA approved HBT’s Abbreviated New Drug Application to market and sell its Fulvestrant product, a generic equivalent to Faslodex®, for the treatment of certain types of breast cancer. In early 2020, through its marketing partner, HBT Labs launched commercial sales of Fulvestrant in the US.
In 2018, HBT Labs filed a New Drug Application with the FDA under Section 505(b)(2) for approval to market and sell HBT’s Paclitaxel product for the treatment of certain types of breast cancer.
In 2018, HBT Labs filed a New Drug Application with the FDA under Section 505(b)(2) for approval to market and sell HBT’s Paclitaxel product for the treatment of certain types of breast cancer.
FULVESTRANT INJECTION
HBT’s Fulvestrant
Container Type | Prefilled Syringe |
Strength | 250 mg per 5 mL |
Concentration | 50 mg per mL |
Fill Volume | 5 mL |
Syringe Size | 5 mL |

Our mission is to develop and deliver cost-effective, high-quality
therapeutics for patients in critical need.